Stunning effects in radioiodine therapy of thyroid carcinoma: Existence, clinical effects and ways out;Stunningeffekte bei der radioiodtherapie des schilddrüsenkarzinoms: Existenz, klinische auswirkungen und auswege

NuklearMedizin

Volumn 42, Issue 1, 2003, Pages 10-14

  Koch, W ^a,b   Knesewitsch, P ^a   Tatsch, K ^a   Hahn, K ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Iodine 123 scintigraphy; Radioiodine therapy; Stunning

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN;

HUMAN; PUBLICATION; REVIEW; STUNNING EFFECT; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR SCINTISCANNING;

EID: 0037329967     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623899     Document Type: Review

References (33)

1. Cailleux AF, Baudin E, Travagli JP et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85: 175-8.
2. 131I. J Nucl Med 2001; 42: 531-3.
3. 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake. Nucl Med Commun 1996; 17: 687.
4. 131I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 2001; 42: 1470-5.
5. Dietlein M, Dressler J, Farahati J et al. Leitlinie zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom. Nuklearmedizin 1999; 38: 221-2.
6. Dörr U, Bach D, Langer T et al. Stunning-Phänomen der Schilddrüse - ist eine Änderung des diagnostischen Konzeptes bei differenzierten Schilddrüsenkarzinomen angezeigt? DGN-Abstracts 2002; 64.
7. Gerard S, Cavalieri R. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med 2002; 27: 1-8.
8. Hermanska J, Karny M, Zimak J et al. Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma. J Nucl Med 2001; 42: 1084-90.
9. 123I. Eur J Nucl Med Mod Imaging 2002; 29: 783-8.
10. 131I. Nucl Med Commun 1996; 17: 839.
11. Jeevanram RK, Shah DH, Sharma SM et al. Influence of large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986; 13: 277-9.
12. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 1998; 37: 23-5.
13. 131I. Eur J Nucl Med 2002; 29: 1421-7.
14. Leger FA, Izembart M, Dagousset F et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25: 242-6.
15. Mandel SJ, Shankar LK, Benard F et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26: 6-9.
16. 123I for the diagnostic evaluation of patients with thyroid cancer. J Nucl Med 1993; 25: 242-6.
17. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87: 1490-8.
18. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18: 505-12.
19. 131I diagnostic whole-body scanning. J Nucl Med 2001; 42: 986.
20. Medvedec M, Grosev D, Loncaric S et al. As soon as possible is already too late. J Nucl Med 2001; 42: 322P.
21. Medvedec M. Thyroid stunning. J Nucl Med 2001; 42: 1129.
22. Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in I-131-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86: 3507-11.
23. Muratet JP, Daver A, Minier JF et al. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39: 1546-50.
24. Pacini F, Capezzone M, Elisei R et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87: 1499-501.
25. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997; 7: 277-80.
26. Park HM, Perkins OW, Edmondson JW et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4: 49-54.
27. 131I irradiation in cultured thyroid epithelial cells. J Nucl Med 2002; 43: 828-34.
28. Robbins RJ, Chon JT, Fleisher M et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma. J Clin Endocrinol Metab 2002; 87: 3242-7.
29. 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 2001; 43: 72-6.
30. 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol 2001; 55: 515-21.
31. Stabin MG, Stubbs JB, Toohey RE. NUREG/CR-6345 Radiation dose estimates for radiopharmaceuticals. Oak Ridge, TN: Radiation internal dose information center. Oak Ridge Institute for Science and Education (1996).
32. Waxman A, Ramanna L, Chapman N et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981; 22: 861-5.
33. Yeung HW, Humm JL, Larson SM. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 2000; 41: 1082.